&nbsp;

ColonCancerTreatmentPathwayMap.pdf

Jun 2023

Document

ColorectalCancerFollow-upCarePathwayMap.pdf

Jun 2023

Document

ColorectalCancerScreeningPathwayMap.pdf

Jun 2023

Document

ColorectalAcknowledgements.pdf

Jun 2023

Regimen

TECL; TECL(RAMP)

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

New Drug Funding Program

Teclistamab (Outpatient) - Relapsed or Refractory Multiple Myeloma

High Cost Therapy Funding Program

Teclistamab (Inpatient) - Relapsed or Refractory Multiple Myeloma

, Collapse Show fewer tags

Drugs Used:

teclistamab

... Show more tags

Quick Link(s):

Regimen Monograph

Jul 2025

Drug

crisantaspase recombinant

Other Name(s): Rylaze™

Quick Link(s):

Drug Monograph, Patient Info Sheet

Jan 2024

Regimen

TRIFTIPI+BEVA

Cancer Type:

Gastrointestinal,

Colorectal,

Small bowel and appendix

Intent: Palliative

Funding:

Exceptional Access Program

trifluridine / tipiracil - In combination with bevacizumab for treatment of metastatic colorectal cancer, according to clinical criteria

New Drug Funding Program

Bevacizumab (Biosimilar) - In Combination with Trifluridine and Tipiracil for Previously Treated Metastatic Colorectal Cancer

trifluridine / tipiracil,

Drugs Used:

bevacizumab

... Show more tags

, Collapse Show fewer tags

Quick Link(s):

Regimen Monograph

Nov 2024

Document

CoP-Fall2023.pdf

Dec 2023

Document

CART-cellTherapyForAdultWithRelapsedRefractoryB-cellALL.pdf

Dec 2023

Document

CART-cellTherapyforPediatricRelapsedRefractoryB-cellALL.pdf

Dec 2023

Regimen

CARFDEXASELI

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

ODB - General Benefit

dexamethasone